| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | IL3RA | Synonyms | CD123, IL-3R-alpha, IL3R, IL3RAY, IL3RX, IL3RY, hIL-3Ra | Type of gene | protein-coding |
| Chromosome | X|Y | Map location | X;Y | dbXrefs | |
| Description | interleukin 3 receptor subunit alpha | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD7 | Synonyms | GP40, LEU-9, TP41, Tp40 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q25.3 | dbXrefs | |
| Description | CD7 molecule | ||||
| GTO ID | GTC3155 |
| Trial ID | NCT05513612 |
| Disease | Multiple Myeloma | Adult T-Cell Leukemia/Lymphoma | B-Cell Non-Hodgkin's Lymphoma | B-Cell Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia |
| Altered gene | CD19|BCMA|CD123|CD7 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies |
| Year | 2022 |
| Country | China |
| Company sponsor | Shanghai Pudong Hospital |
| Other ID(s) | 2020-IIT-002-E03 |
| Cohort 1 | |||||||||||
|
|||||||||||